FDA Approves Orilissa (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis
NORTH CHICAGO, Ill., July 24, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced that the U.S. Food and Drug Administration (FDA)...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Brain | Drugs & Pharmacology | Endometriosis | Food and Drug Administration (FDA) | Neurology | Pain | Pain Management